bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Patient Education

  • Educate patient about the nature of the chronic bronchitis (the progressive nature and its potential impact on future lifestyle and function)
  • Review with the patient the signs of onset of infection (eg increased purulence, viscosity or volume of secretions) that should be treated early
  • Discuss measures that may limit the spread of viral infections (eg hand washing)
  • Encourage patients to exercise regularly
    • Although not accompanied by measurable improvement in lung function, it will increase exercise tolerance and improve the patient’s sense of well-being

Lifestyle Modification

Smoking Cessation

  • A discussion of smoking behavior and the setting of a specific cessation date should be part of every physician-patient encounter
  • Patients presenting with AECB should be encouraged to stop smoking since it is the most effective way to reduce the risk of future morbidity from chronic bronchitis
  • It can lead to dramatic symptomatic benefits for patients with chronic bronchitis eg stopping cough in 94-100%; when coughing stops, it can occur in as quickly as 4 weeks in 54% of patients

Reduction/Elimination of Irritants

  • Reduction or elimination of any source of irritants that may worsen lower airway inflammation
    • Includes environmental pollutants (eg dust, pollutants and second-hand smoke) and occupational irritants
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.